|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of this pilot study suggest that a larger scale prospective investigation of the effect of mdr1 gene expression on outcome in osteosarcoma is warranted.
|
8100852 |
1993 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that, in osteosarcoma, the MDR phenotype is not associated with a more aggressive behavior both in vitro and in clinical settings, suggesting that the previously shown association of the MDR phenotype with a worse outcome in osteosarcoma is not related to a higher metastatic ability of cells with P-glycoprotein overexpression but is more likely due to their lack of responsiveness to cytotoxic drugs.
|
8625324 |
1996 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Resistance to several cytotoxic agents (MultiDrug Resistance MDR), including anthracyclines, vinca alkaloids and epipodophylline derivatives can occur in human osteosarcoma (OS) cells, detected by the overexpression of a 170 kD glycoprotein (p170), as a result of increased expression of the MDR gene (mdr1).
|
8669809 |
1996 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a retrospective study, we correlated P-glycoprotein expression with the outcome of conventional chemotherapy in 62 consecutive, clinically staged patients diagnosed as having osteosarcoma between 1980 and 1989.
|
9390540 |
1997 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that P-Gp/MDR1 overexpression is related to multidrug resistance in human osteosarcoma in vivo.
|
9458350 |
1998 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Only increased expression of P-glycoprotein in tumor cells was significantly associated with a poor outcome, further supporting the adverse prognostic value of this marker in osteosarcoma.
|
9917506 |
1999 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.
|
9989824 |
1999 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the subcellular localization of P-glycoprotein, in a series of U-2 OS osteosarcoma cell clones transfected with MDR1 gene in order to verify whether the nucleus is a constant site for the localization and functional activity of P-glycoprotein, and in which way some aspects of cell morphology related to MDR depend on the subcellular P-glycoprotein localization rather than on the exposure to the selective drug.
|
10321019 |
1999 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of YB-1 is correlated with MDR-1 gene expression in breast cancer and osteosarcoma.
|
10597187 |
1999 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
|
10697541 |
2000 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study represents the first prospective assessment of the prognostic value of MDR1 mRNA expression in patients with newly diagnosed extremity osteosarcoma.
|
10894867 |
2000 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study we explored the correlation between (99m)Tc-MIBI clearance and histological necrosis following induction chemotherapy and P-glycoprotein expression in osteosarcoma.
|
11595696 |
2001 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intracellular pH regulation in U-2 OS human osteosarcoma cells transfected with P-glycoprotein.
|
11853886 |
2002 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of the Y-box-binding protein (YB-1) has been reported to correlate with the expression of P-glycoprotein in breast cancer and osteosarcoma.
|
12533839 |
2003 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes.
|
12695554 |
2003 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study the U2OS human osteosarcoma cell line and its multidrug resistant (MDR) subline that overexpresses MDR-1 gene, MDR-U2OS, have been analyzed for their responsiveness to TRAIL.
|
15547696 |
2004 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Event-free survival analyses revealed a prognostic value for HER2 and/or P-glycoprotein expression in OS, but not in ES.
|
15913990 |
2005 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin.
|
16049968 |
2006 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The chemosensitivity of OS cells to DOX was strongly dependent on mRNA MDR1 expression and could be circumvented by adding CsA.
|
17045162 |
2006 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the osteosarcoma cell lines, etoposide and doxorubicin were better inducers of P450 3A4 and MDR1 than rifampin. siRNA against PXR down-regulated P450 3A4 expression only in the osteosarcoma cell line.
|
17279585 |
2007 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function.
|
17703109 |
2007 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to establish human FK228-resistant osteosarcoma cell lines and to investigate whether there are mechanisms of FK228 resistance in addition to P-gp up-regulation.
|
19073909 |
2009 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overexpression of the ezrin deletion mutant entirely restored drug susceptibility of osteosarcoma cells, consistent with Pgp dislocation to cytoplasmic compartments and abrogation of G(M1) /Pgp co-localization at the plasma membrane.
|
21780101 |
2012 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
siRNA down-regulated MDR1 mRNA expression by 50% in breast carcinoma and osteosarcoma cell lines, and significantly inhibited tumor cell proliferation up to 90% (p<0.01), when co-administered with doxorubicin or methotrexate, despite the known chemoresistance of the cell lines. siRNAs reduced the IC₅₀ of doxorubicin and methotrexate by more than 10-fold (p<0.01).
|
21868524 |
2011 |
|
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.
|
22016816 |
2011 |